Drug updated on 11/1/2024
| Dosage Form | Tablet (oral; 500 mg, 1000 mg) |
| Drug Class | Iron chelators |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of transfusional iron overload in adult and pediatric patients 8 years of age and older with thalassemia syndromes, sickle cell disease or other anemias.
Latest News
Summary
- This summary is based on the review of four systematic review(s)/meta-analysis(es). [1-4]
- Iron Chelation Therapy (ICT) in Thalassemia Patients: Deferiprone showed high compliance rates (87.2-92.2%) compared to desferioxamine (48.84-85.1%) and deferasirox (90-100%). Increased compliance correlated with lower serum ferritin levels, reduced risks of liver and cardiac diseases, endocrinologic morbidity, and improved health-related quality of life (HRQoL).
- Friedreich Ataxia (FA): Deferiprone showed no significant improvement across severity scales (ICARS, FARS, SARA, ADL), with most studies reporting patient deterioration regardless of intervention or inconclusive results.
- Sickle Cell Disease (SCD) and Thalassemia: Adherence rates for deferiprone ranged from 69% to 95% compared to deferoxamine (71% to 93%), with trials reporting no difference in quality of life (QoL) outcomes.
- Friedreich Ataxia (FA): Serious adverse events (SAEs) reported with deferiprone include atrial fibrillation, craniocerebral injury, and ventricular tachycardia.
- Sickle Cell Disease (SCD), Thalassemia, and Superficial Siderosis: SAEs associated with deferiprone include a 1-2% risk of agranulocytosis in SCD and thalassemia, with superficial siderosis patients experiencing a 21.7% incidence of anemia, 8.7% incidence of neutropenia, and 5.8% incidence of agranulocytosis.
- There is no population type or subgroup information available in the reviewed studies.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ferriprox (deferiprone) Prescribing Information. | 2021 | Chiesi USA, Inc., Cary, NC |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| The impact of chelation compliance in health outcome and health related quality of life in thalassaemia patients: a systematic review | 2024 | Health and Quality of Life Outcomes |
| Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia | 2023 | The Cochrane Database of Systematic Reviews |
| Clinical evidence of interventions assessed in Friedreich ataxia: a systematic review | 2022 | Therapeutic Advances in Rare Disease |
| Treatment Response of Deferiprone in Infratentorial Superficial Siderosis: a Systematic Review | 2021 | Cerebellum |